Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risk-adapted therapy withdrawal in juvenile idiopathic arthritis using S100A12 and hsCRP
NL-OMON40476Active, not recruiting
- Sponsor
- Universität Münster
- Start
- Jul 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label trial of methotrexate, etanercept and adalimumab in juvenile idiopathic arthritis (JIA) (2 arms), sponsored by Universität Münster. Primary endpoints: Disease flare after treatment withdrawal or continuation, Clinical remission on medication and 3 more. Started Jul 2014; status: active, not recruiting.
02
Drugs
03
Conditions
juvenile idiopathic arthritis (JIA)
Beyond the preview
Go deeper on NL-OMON40476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40476.